trending Market Intelligence /marketintelligence/en/news-insights/trending/f3kkq2hmybwmohzoofhspg2 content esgSubNav
In This List

US FDA flags deficiencies in Mylan's generic of GSK's Advair Diskus

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


US FDA flags deficiencies in Mylan's generic of GSK's Advair Diskus

The U.S. Food and Drug Administration has found minor deficiencies in Mylan NV's application for a generic version of GlaxoSmithKline PLC's blockbuster asthma treatment Advair Diskus.

Advair Diskus generated £3.13 billion in full-year 2017 global revenues, including £1.61 billion in the U.S.

Canonsburg, Pa.-based Mylan said it expects the regulator to issue a complete response letter identifying the issues on June 27.

The application for the product has received a priority designation, and Mylan believes it could get approval for the treatment before the standard 90-day time period after the date of its response to the FDA's letter.

In February, the FDA rejected Novartis AG's application for a generic version of Advair.